CA-AQUANTIA-CORP.
29.1.2018 15:02:10 CET | Business Wire | Press release
Aquantia Corp., (NYSE: AQ), a leader in high-speed, Multi-Gigabit Ethernet connectivity solutions, today introduced a suite of products targeted at autonomous vehicle platforms. Earlier today, Aquantia also announced a collaboration with NVIDIA to provide Multi-Gig networking support for the NVIDIA DRIVE Xavier™ and DRIVE Pegasus platforms. These high-performance computing platforms featuring Aquantia Multi-Gig networking will be available to automotive partners starting in the first quarter of 2018.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180129005359/en/
The AQcelerate Automotive product line includes the following high-performance networking devices, which all support data rates up to 10GbE:
- The AQV107 Multi-Gig PHY
- The AQVC107 PCIe Multi-Gig MAC+PHY Ethernet controller
- The AQVC100 PCIe Multi-Gig controller (MAC only)
“The number one feature for self-driving vehicles is safety,” said Faraj Aalaei, Chairman and CEO of Aquantia Corp. “Vehicle sensors and cameras collect huge amounts of data that need instant processing to allow the vehicle to make critical decisions that ensure the safety of the driver, passengers, and anyone else sharing the road. Moving data between the sensors and the compute nodes within the In-Vehicle Network (IVN) requires Multi-Gig capabilities to deliver a safe and secure driving experience.”
The introduction of these products creates a new era of Multi-Gig networking devices to support the development of autonomous vehicles. By adopting Aquantia’s industry proven, high-performance Ethernet solutions, automotive OEMs can enable the deployment of next generation networking architectures to provide a new level of passenger safety and security that is becoming a critical requirement for Level 4 and Level 5 self-driving vehicles.
Moving to Level 4 and Level 5 autonomous driving requires a new network architecture that can support:
- High-bandwidth requirements for the IVN to support the increasing number of sensors and high-resolution cameras.
- Redundancy of all the function-critical components and systems to provide the utmost levels of safety.
- Simplification and security – moving from multiple network interfaces into an industry proven, coherent, secure network that supports all the required features of autonomous driving.
These requirements are driving the industry towards Multi-Gig Ethernet over copper – the perfect fit for Aquantia’s deep networking expertise, knowledge, and experience.
The autonomous driving ecosystem is growing to include more OEM car manufacturers, Tier-1 suppliers, GPU/CPU companies and high-performance networking silicon suppliers as the requirements become more stringent. The potential market opportunity is considerable. Raymond James estimates that the silicon content in autonomous vehicles will represent a $30 billion total addressable market by 2030. 1
Earlier this month, Aquantia also announced a collaboration with Molex on a 10 Gbps Automotive Ethernet Network at CES. This week, Aquantia will demonstrate these new products at the Automotive Ethernet Congress in Munich. Learn more about Multi-Gig AQcelerate products here .
About Aquantia
Aquantia is a leader in the design, development and marketing of advanced, high-speed communications ICs for Ethernet connectivity in the Data Center, Enterprise Infrastructure, Access and Automotive markets. Aquantia products are designed to cost-effectively deliver leading-edge data speeds for use in the latest generation of communications infrastructure to alleviate network bandwidth bottlenecks caused by the growth of global IP traffic and in emerging and demanding applications such as autonomous driving. Aquantia is headquartered in Silicon Valley. For more information, visit www.aquantia.com .
(AQ-INV)
1 Source: Raymond James, From ADAS to Autonomous: A 25-Year Forecast and Full Value Chain Analysis, The 2017 Version—March 2017
View source version on businesswire.com: http://www.businesswire.com/news/home/20180129005359/en/
Contact:
Aquantia Corporate Communications:
Diane Vanasse,
408-242-0027
dvanasse@aquantia.com
or
Aquantia
Investor Relations:
Deborah Stapleton, 650-815-1239
deb@stapleton.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom